A pivotal trial comparing nivolumab, an inhibitor of the receptor for programmed cell death protein 1 (PD-1), and dacarbazine in previously untreated advanced melanoma yielded even more impressive results, demonstrating a 58% reduction in the survival hazard in favor of the immune checkpoint inhibitor (Robert et al., 2015a). This evidence concerns the gene PDCD1 and melanoma.